

**DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED**

Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad-380 009

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2010**

(Rupees in Lacs)

Sr. No.	PARTICULARS	STANDALONE			CONSOLIDATED		
		For the quarter ended 30-06-2010	Corresponding 3 months ended in the previous year 30-06-2009	For the Year ended 31-03-2010	For the quarter ended 30-06-2010	Corresponding 3 months ended in the previous year 30-06-2009	For the Year ended 31-03-2010
		Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited
<b>1</b>	<b>a) Net Sales/Income From Operations</b>	<b>7,101.43</b>	<b>7,343.71</b>	<b>35,260.88</b>	<b>20,188.42</b>	<b>22,771.47</b>	<b>91,535.74</b>
	b) Other Operating Income	19.35	22.59	315.28	1,038.52	1,548.38	2,693.46
	c) Income from Associates	-	-	-	0.38	(0.01)	4.91
	<b>Total Income (a+b+c)</b>	<b>7,120.78</b>	<b>7,366.29</b>	<b>35,576.16</b>	<b>21,227.32</b>	<b>24,319.84</b>	<b>94,234.11</b>
<b>2</b>	<b>Expenditure</b>						
	a) (Increase)/Decrease in Stock in trade and work in progress	(517.72)	47.64	1,287.47	(620.91)	(505.91)	700.99
	b) Consumption of Raw Materials	3,206.56	2,417.19	12,280.46	6,069.41	5,953.60	23,177.78
	c) Purchase of traded goods	10.73	58.60	246.97	140.20	165.16	3,796.36
	d) Employees Cost	907.33	820.74	3,371.31	6,314.23	7,402.74	25,405.80
	e) Depreciation	653.64	529.76	2,064.10	1,610.38	1,452.52	5,941.60
	f) Other Expenditure	1,269.55	1,615.46	6,347.98	3,839.12	4,435.20	18,077.06
	<b>g) Total</b>	<b>5,530.09</b>	<b>5,489.39</b>	<b>25,598.29</b>	<b>17,352.43</b>	<b>18,903.31</b>	<b>77,099.59</b>
<b>3</b>	<b>Profit from Operations before Other Income, Interest and Exceptional Items (1-2)</b>	<b>1,590.69</b>	<b>1,876.90</b>	<b>9,977.87</b>	<b>3,874.89</b>	<b>5,416.53</b>	<b>17,134.52</b>
<b>4</b>	<b>Other Income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>5</b>	<b>Profit before Interest and Exceptional Items (3+4)</b>	<b>1,590.69</b>	<b>1,876.90</b>	<b>9,977.87</b>	<b>3,874.89</b>	<b>5,416.53</b>	<b>17,134.52</b>
<b>6</b>	<b>Interest &amp; Financial Charges (Net)</b>	<b>530.26</b>	<b>522.71</b>	<b>2,037.18</b>	<b>820.32</b>	<b>1,035.26</b>	<b>3,876.73</b>
<b>7</b>	<b>Profit after Interest but before Exceptional Items (5-6)</b>	<b>1,060.44</b>	<b>1,354.19</b>	<b>7,940.69</b>	<b>3,054.57</b>	<b>4,381.27</b>	<b>13,257.79</b>
<b>8</b>	<b>Exceptional Items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>9</b>	<b>Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)</b>	<b>1,060.44</b>	<b>1,354.19</b>	<b>7,940.69</b>	<b>3,054.57</b>	<b>4,381.27</b>	<b>13,257.79</b>
<b>10</b>	<b>Tax expense</b>	<b>111.16</b>	<b>95.00</b>	<b>903.82</b>	<b>340.66</b>	<b>460.65</b>	<b>1,495.25</b>
	- Current Tax	58.93	92.55	217.47	171.78	92.64	342.70
	- Deferred	52.24	1.20	683.25	168.88	366.76	1,149.45
	- Wealth	-	1.25	3.10	-	1.25	3.10
<b>11</b>	<b>Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)</b>	<b>949.27</b>	<b>1,259.19</b>	<b>7,036.87</b>	<b>2,713.91</b>	<b>3,920.62</b>	<b>11,762.54</b>
<b>12</b>	<b>a) Extraordinary Items (net of tax expense Rs.____)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	b) Prior Period Expenses	(11.18)	5.46	(110.00)	(11.08)	5.49	(171.68)
	c) Short provision of Income Tax	-	-	39.52	-	-	196.72
<b>13</b>	<b>Net Profit (+)/ Loss (-) for the period (11-12)</b>	<b>960.45</b>	<b>1,253.73</b>	<b>7,107.35</b>	<b>2,724.99</b>	<b>3,915.13</b>	<b>11,737.50</b>
<b>14</b>	<b>Paid-up Equity Share Capital (Face Value of Rs 2/- per equity share)</b>	<b>1,613.94</b>	<b>1,613.94</b>	<b>1,613.94</b>	<b>1,613.94</b>	<b>1,613.94</b>	<b>1,613.94</b>
<b>15</b>	<b>Reserves Excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	<b>-</b>	<b>-</b>	<b>59,507.70</b>	<b>-</b>	<b>-</b>	<b>75,480.04</b>
<b>16</b>	<b>Basic and Diluted EPS (before &amp; after Extraordinary Items)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	Basic EPS (in Rs.Not annualised)	1.19	1.56	8.81	3.38	4.85	18.13
	Diluted EPS (in Rs.Not annualised)	1.18	1.54	8.74	3.35	4.82	17.99
<b>17</b>	<b>Public Shareholding</b>						
	- Number of Equity Shares	31,555,667	31,655,667	31,555,667	31,555,667	31,655,667	31,555,667
	- Percentage of Shareholding	39.10	39.23	39.10	39.10	39.23	39.10
<b>18</b>	<b>Promoters and promoter group Shareholding</b>						
	a) Pledged/Encumbered						
	- Number of Equity Shares	2,500,000	5,200,000	2,500,000	2,500,000	5,200,000	2,500,000
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	5.09%	10.60%	5.09%	5.09%	10.60%	5.09%
	- Percentage of Shares (as a % of the total share capital of the company)	3.10%	6.44%	3.10%	3.10%	6.44%	3.10%
	b) Non-encumbered	-	-	-	-	-	-
	- Number of Equity Shares	46,641,469	43,841,469	46,641,469	46,641,469	43,841,469	46,641,469
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	94.91%	89.40%	94.91%	94.91%	89.40%	94.91%
	- Percentage of Shares (as a % of the total share capital of the company)	57.80%	54.33%	57.80%	57.80%	54.33%	57.80%

**Segment wise Revenue ,Result and Capital Employed**

Sr. No	PARTICULARS	For the	Corresponding	For the Year	For the	Corresponding	For the Year
		quarter ended	3 months	ended 31	quarter	3 months	ended 31-
		30-06-2010	ended in the	03-2010	ended	in the previous	ended 31-
		Unaudited	30-06-2009	Audited	30-06-2010	year 06-2009	03-2010
			Unaudited		Unaudited	Unaudited	Audited
<b>1</b>	<b>Segment Revenue</b>						
	(a) CRAMS	4,747.84	5,341.05	25,701.86	14,268.98	16,835.14	66,293.81
	(b) Marketable Molecules (MM)	2,353.59	2,002.66	9,559.03	5,919.44	5,936.33	25,241.93
	(c) Others	-	-	-	-	-	-
	<b>Total</b>	<b>7,101.43</b>	<b>7,343.71</b>	<b>35,260.88</b>	<b>20,188.42</b>	<b>22,771.47</b>	<b>91,535.74</b>
	<b>Less: Inter-segment Revenue</b>	-	-	-	-	-	-
	<b>Net Sales /Income from Operation</b>	<b>7,101.43</b>	<b>7,343.71</b>	<b>35,260.88</b>	<b>20,188.42</b>	<b>22,771.47</b>	<b>91,535.74</b>
<b>2</b>	<b>Segment Results {(Profit)(+)/(Loss)(-) before tax and interest from each segment}</b>						
	(a) CRAMS*	1,333.78	1,555.91	8,130.38	2,698.07	3,916.54	13,443.99
	(b) Marketable Molecules (MM)*	256.92	320.99	1,797.48	1,176.42	1,499.99	3,635.73
	(c) Others	-	-	-	-	-	-
	<b>Total</b>	<b>1,590.69</b>	<b>1,876.90</b>	<b>9,927.87</b>	<b>3,874.51</b>	<b>5,416.53</b>	<b>17,079.72</b>
	Less: i) Interest	530.26	522.71	2,037.18	820.32	1,035.26	3,876.73
	ii) Other un-allocable expenditure net off un-allocable income	-	-	(50.00)	(0.38)	-	(54.80)
	<b>Total Profit Before Tax</b>	<b>1,060.44</b>	<b>1,354.19</b>	<b>7,940.68</b>	<b>3,054.57</b>	<b>4,381.27</b>	<b>13,257.79</b>
<b>3</b>	<b>Capital Employed (Segment Assets-Segment liabilities)</b>						
	(a) CRAMS	51,402.34	44,771.32	51,605.07	88,570.53	87,147.91	86,697.00
	(b) Marketable Molecules (MM)	12,143.88	11,015.63	11,398.97	23,442.15	24,194.83	24,968.34
	(c) Others	51,553.48	34,346.19	42,827.23	53,968.97	37,854.99	45,284.23
	<b>Total</b>	<b>115,099.70</b>	<b>90,133.14</b>	<b>105,831.27</b>	<b>165,981.65</b>	<b>149,197.73</b>	<b>156,949.57</b>
	* Includes Forex (Loss) / Gain						
On behalf of the Board							
Place: Ahmedabad Date: 12th August, 2010				Janmejay R Vyas Chairman & Managing Director			